Objective: This study aimed to examine regulation of capillary tubules and lipid formation in vascular endothelial cells and macrophages via extracellular vesicle-mediated microRNA (miRNA)-4306 transfer Methods: Whole blood samples (12 mL) were collected from 53 patients, and miR-4306 levels in extracellular vesicles (EVs) were analyzed by reverse transcription-polymerase chain reaction. Human coronary artery vascular endothelial cells (HCAECs) and human monocyte-derived macrophages (HMDMs) were transfected with a scrambled oligonucleotide, an miR-4306 mimic, or an anti-miR-4306 inhibitor. The direct effect of miR-4306 on the target gene was analyzed by a dual-luciferase reporter assay. Results: EV-contained miR-4306 released from HMDMs was significantly upregulated in coronary artery disease. Oxidized low-density lipoprotein (ox-LDL)-stimulated HMDM-derived EVs inhibited proliferation, migration, and angiogenesis abilities of HCAECs in vitro. However, ox-LDLstimulated HCAEC-derived EVs enhanced lipid formation of HMDMs. The possible mechanism of
Introduction
MicroRNAs (miRNAs), which are a class of small, non-coding RNAs that are approximately 21 to 25 nucleotides in length, regulate translation of mRNA and protein in plants and animals. 1 An increasing body of evidence indicates that circulating miRNAs play a pivotal role in cell-to-cell communication in coronary artery disease (CAD). 2 Endothelial release of miR126 bound to the protein argonaute 2 modulates smooth muscle gene expression and promotes a proatherogenic phenotype in smooth muscle cells. 3 mRNA regulatory Ago2•miRNA-223 complexes can be transported by activated platelets to endothelial cells. 4 Extracellular vesicles (EVs) are nanovesicles of endocytic origin that are released from most cell types. 5 Circulating EVs released from erythrocytes, leukocytes, platelets, and endothelial cells carry a multitude of biological information to alter the pathophysiological processes of CAD. 6 EVs are the main extracellular vehicles for distinct miRNAs in the circulation. 7 In this study, we investigated whether there is functional transfer of EVs and EV-derived miRNA-4306 between human monocyte-derived macrophages (HMDMs) and human coronary artery vascular endothelial cells (HCAECs).
Methods

Patients
We recruited 53 patients who underwent diagnostic coronary angiography and were admitted to our hospital between July 2015 and July 2016. Patients were classified into three groups as follows. (1) The control group comprised patients who had chest pain syndrome with normal coronary artery findings (n ¼ 15). ( 2) The elective percutaneous intervention (PCI) group comprised patients who had PCI performed within 2 weeks (n ¼ 15). ( 3) The emergency PCI group comprised patients who had PCI performed within 12 hours (n ¼ 20) (Supplementary Table  1 ). The PCI groups included patients who exclusively had effort-related angina with a positive exercise stress test and at least one coronary stenosis was detected at angiography with > 70% reduction of the lumen diameter. Additionally, patients in the PCI groups had chest pain lasting for > 30 minutes within 24 hours before enrollment and a large rise in troponin I levels. A total of 20 mL of whole fasting blood samples were collected from 53 patients. HMDMs from each donor were immediately isolated from venous blood and placed in RPMI 1640 medium. The protocol was approved by the Ethics Committee of West China Hospital. Written informed consent was obtained from each patient.
Cell culture
HCAECs were purchased from the Cell Bank of the Chinese Academy of Sciences (Chengdu, China). HMDMs were isolated from donors. Briefly, monocytes were first extracted from peripheral blood samples and then allowed to adhere to cell culture plates for 4 days in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO, USA) containing 10% fetal bovine serum (FBS) (Cell Culture Bioscience, Shanghai, China), 5% human AB serum (Sigma-Aldrich), antibiotics, GlutaMax (Gibco, Grand Island, NY, USA), and recombinant human macrophage colony-stimulating factor (M-CSF; PeproTech, Rocky Hill, NJ, USA). The monocytes were then resuspended in RPMI 1640 medium containing 10% FBS and further cultured for 2 days. The cell culture medium was then replaced with RPMI 1640 supplemented with 5% FBS for 1 day.
Isolation and characterization of EVs
HMDMs and HCAECs were exposed to 100 mg/mL oxidized low-density lipoprotein (ox-LDL) for 12 hours, followed by centrifugation at 400 Â g for 5 minutes. The cells were ultracentrifuged at 2000 Â g for 20 minutes to remove cellular debris. After washing of the EV pellets with phosphatebuffered saline at 110,000 Â g for 2 hours, the supernatant was ultracentrifuged at 110,000 Â g for 2 hours at 4 C. Protein content of the EVs was used to normalize for EV quantity between experiments using the Pierce microplate bicinchoninic acid protein assay kit (Thermo Fisher Scientific, USA, Rockford, IL, USA). The activation status and origin of the EV fractions were detected by flow cytometry. EVs from HMDMs or HCAECs were labelled with CD45-FITC or CD31-FITC. The samples were then detected cytofluorometrically using a flow cytometer (BD Biosciences, San Jose, CA, USA).
Fluorescence labelling of EVs and microscopy
Cultured HMDMs or HCAECs were labelled with DiI-C16 for 30 minutes. The supernatant was collected and centrifuged to isolate EVs. Human monocyte-EVs (HM-EVs/endothelial cell-EVs (EC-EVs) in the medium were incubated with HCAECs or HMDMs. After incubation for 12 hours, HMDMs or HCAECs were washed, fixed, and observed by microscopy (Olympus, Tokyo, Japan).
For electron microscopy, the EV pellet was placed in a droplet of 2.5% glutaraldehyde in phosphate-buffered saline at a pH of 7.2 and fixed overnight at 4 C. The samples were then embedded in 10% gelatin and fixed in glutaraldehyde at 4 C and cut into several blocks (<1 mm 3 ). The samples were dehydrated for 10 minutes for each step in increasing concentrations of alcohol (30%, 50%, 70%, 90%, 95%, and 100% Â 3). Samples were embedded in pure, fresh Quetol-812 epoxy resin and polymerized at 35 C for 12 hours, 45 C for 12 hours, and 60 C for 24 hours. Ultrathin sections (100 nm) were cut using a Leica EM UC7 ultra-microtome (Leica Microsystems, Beijing, China) and poststained with uranyl acetate for 10 minutes and with lead citrate for 5 minutes at room temperature before observation with a FEI Tecnai T20 transmission electron microscope equipped with a Gatan UltraScan 894 CCD (Thermo Fisher Scientific, Waltham, MA, USA), operated at 120 kV. 
Bromodeoxyuridine incorporation assay
Transwell migration assay
The migration ability of HMDMs was measured in a Transwell Chamber (6.5 mm, Costar;
Sigma-Aldrich). MicroRNA (mimics or inhibitor), vascular endothelial growth factor A (VEGFA) small interfering RNA, HCAEC-derived EVs, and/or their respective controls were transfected into HMDMs. Transfected cells were cultured in Dulbecco's modified Eagles medium (DMEM) supplemented with 0.5% serum for 24 hours and harvested by trypsinization. An aliquot (250,000 cells/200 mL) of the cells in serum-free DMEM was dispensed into the transwell inserts (8-mm pore size) that were precoated with 0.5% gelatin (G1393; Sigma-Aldrich), and DMEM (600 mL) with 20% FBS was placed in the lower chamber. The transwell plates were incubated at 37 C in a 5% CO 2 incubator for 18 to 24 hours. Cells remaining on the upper surface of the filter membrane (nonmigrant) were gently scraped off with a cotton swab. Images of migrant cells were captured by a photomicroscope (BX51; Olympus). Cell migration was quantified by blind counting of the migrated cells on the lower surface of the membrane, with five fields per chamber.
Capillary tube formation assay
Briefly, at least 30 minutes before the experiment, each well of a 24-well plate was coated with 100 mL of Matrigel (BD Biosciences) at 37 C. HCAECs were pretreated in the presence of HMDM EVs (20 mg of total protein per well) or a saline solution in starvation medium at 37 C for 24 hours. HCAECs were seeded onto the plated Matrigel at a concentration of 1 Â 10 5 cells/well, and each treatment was repeated in three wells. After 6 hours, images of formation of capillary-like structures were examined under a light microscope (Olympus) at 200Â magnification. 
Transfection and vector construction
Plasmid construction and luciferase assay
The DNA sequence of the entire human VEGFA 3 0 -UTR was amplified by polymerase chain reaction (PCR). The amplified DNA sequences were inserted into the p-MIR-report plasmid (Sangon Biotech, Shanghai, China). For luciferase reporter assays, 293T cells were cotransfected with an individual reporter gene (pmiR-Luc-VEGFA-WT, pmiR-Luc-VEGFA-MUT1, or pmiR-Luc-VEGFA-MUT2), a control, or miR-4306 mimics using TransIT-X2 transfection reagent (Invitrogen).
The pGL4.74(hRluc/TK) plasmid, a control luciferase plasmid, and the pGL4.32(luc2P/NF-jB-RE/Hygro) plasmid (Invitrogen) were transfected using Lipofectamine 2000 reagent (Sangon Biotech). A Renilla plasmid (Invitrogen) was used as an internal control for all transfection assays. After transfection for 48 hours, the activities of luciferase and Renilla were tested using a standard protocol (Sangon Biotech).
RNA isolation and quantitative reverse transcription-PCR
Total RNA isolation from HM-EVs and EC-EVs was performed using TRIzol reagent (Invitrogen), and isolation from the supernatant fraction was performed using an mirVana PARIS kit (Invitrogen). A total of 1 mg of RNA was reversely transcribed into cDNA (TaKaRa Biotechnology Ltd., Dalian, China) after DNase I treatment (Invitrogen). MicroRNA-4306 was detected by quantitative reverse transcription (qRT)-PCR using a miScript Primer Assay kit and SYBR Green (Qiagen, Dusseldorf, Germany). Small nuclear RNA U6 (RNU6) was used as a reference gene with the following primers: RNA U6 primers, forward -5′-CT CGCTTCGGCAGCACA-3′ and reverse -5′-AACGCTTCACGAATTTGCGT-3′; and miR-4306 RT primer, 5′-CTCAACTGGTGTCGTGGAGTCGGC AATTCAGTTGAGGGTACAGA-3′. The forward primer 5′-GCCGAGAAGCUGC UUAGUGU-3′ and reverse primer 5′-CTCAACTGGTGTCGTGGA-3′ were also used. The following program was used: 10 minutes of initial denaturation and enzyme activation at 95 C, followed by 40 cycles composed of 15 
Cholesterol content analysis
HMDMs were stained with oil red O (ORO) and hematoxylin following a routine procedure. HMDMs with a lipid droplet area of more than the width of the nucleus were defined as OROpositive (OROþ).
The components of lipoprotein, free cholesterol (FC), and total cholesterol (TC) in high-performance liquid chromatography were recorded continuously over time. Cholesterol ester (CE) was calculated by subtraction of FC from TC. Briefly, HMDMs were sonicated and lysed and proteins and triglycerides were removed from HMDM lysates. FC was extracted after being dissolved in a solution of isopropanol and n-hexane (1:4, V/V). TC was obtained from an aliquot sample that was treated with cholesterol esterase. Samples were dissolved in a mobile phase containing acetonitrile: isopropanol: n-heptane (52: 35: 12, V/V). A chromatography system (VARIAN Prostar 210; Carlsbad, CA, USA) was used to analyze TC and FC levels.
Statistical analysis
All data were analyzed using SPSS for Windows, Version 16.0 (SPSS Inc., Chicago, IL, USA). The data are presented as the mean AE standard deviation of three independent experiments. Analysis of variance was used for comparisons. A value of p < 0.05 was considered significant.
Results
Patients' characteristics
The mean (standard deviation) age of the patients was 60.2 AE 10.2 years and 54% were men and 46% were women.
HM-EVs from patients with CAD show a reduced capacity for promoting angiogenesis in HCAECs compared with those from controls To examine whether HMDMs secrete EVs that are taken up by HCAECs, a predominant population of EVs derived from HMDMs (HM-EVs) with leukocyte glycoprotein CD45 surface expression was found to be of monocyte origin by flow cytometry ( Figure 1A ). Confocal analysis showed that the HCAECs took up membrane-labelled EVs ( Figure 1B-a, b) . Electron microscopy showed that the separated EVs appeared as a cluster of vesicles of 30 to 100 nm in diameter and were swallowed by HCAECs ( Figure 1C-a, b) . Proliferation, migration, and angiogenesis capabilities of HCAECs treated with HMEVs that were isolated from patients with CAD were compared with those from the control group (Figure 2A-D, E-d-f, F-e-g ). Proliferation of HCAECs that were treated with HM-EVs isolated from patients who had emergency PCI and those with elective PCI was significantly attenuated compared with those from the control group (p < 0.05 and p < 0.01, respectively, Figure 2A-B) . The migration rates of HCAECs that were treated with HM-EVs isolated from patients who had emergency PCI and those with elective PCI were significantly lower than those from the control group (p < 0.05 and p < 0.05, respectively, Figure 2C , 2E-d-f). Tube formation of HCAECs that were treated with HM-EVs isolated from patients who had emergency PCI and those with elective PCI was significantly suppressed compared with those from the control group (p < 0.05 and p < 0.01, respectively, Figure  2D , 2F-e-g). Furthermore, HM-EVs from patients with emergency PCI showed a significantly reduced capacity for promoting angiogenesis in HCAECs compared with those from patients with elective PCI ( Figure 2D , F-e-g, p < 0.05). We also observed that expression of HM-EVderived miR-4306 was higher in patients with CAD compared with the control group (p < 0.05). Moreover, miR-4306 showed higher levels in HM-EVs from patients with emergency PCI than in those from patients with elective PCI ( Figure 1D , p < 0.05).
EVs from ox-LDL-stimulated HMDMs reduce proliferation, migration, and capillary tubule formation of HCAECs by upregulation of nuclear factor kappa B
To determine the effects of HM-EVs on HCAEC activation, HCAECs were incubated with ox-LDL-stimulated HM-EVs.
We found that proliferation, migration, and angiogenesis abilities of HCAECs treated with ox-LDL-stimulated HM-EVs were attenuated compared with those treated with HM-EVs from unstimulated HMDMs (Figure 2A-D, E-a-c, F-a-c) . We further tested whether HM-EVs had an effect on activity of a nuclear factor kappa B (NF-jB)-dependent luciferase reporter. We found that ox-LDLstimulated HM-EVs to HCAECs increased basal and ox-LDL-stimulated activity of the reporter ( Figure 3A) . We then assessed whether the effects of HM-EVs could be repeated by inhibiting NF-jB signaling. Induction of proliferation, migration, and capillary tubule formation in ox-LDL- 
Ox-LDL-stimulated HCAEC-derived extracellular vesicles (EC-EVs) promote HMDM lipid accumulation by upregulation of NF-jB
In flow cytometry, surface expression of glycoprotein CD61 on isolated EVs from HCAEC culture medium showed the vascular endothelial cell origin of these EVs ( Figure 4A-a, b) . We then marked ECEVs with DiI-C16 and tested the localization of fluorescent EC-EVs in HMDMs after incubation ( Figure 4B-c,  d ). Under electron microscopy, isolated EVs were approximately 50 to 300 nm in size and were engulfed by HMDMs ( Figure 4C-c, d) .
To examine the effects of EC-EVs on HMDM lipid accumulation, we directly viewed the lipoprotein content in HMDMs when treated with 100 mg/mL ox-LDL in the (ox-LDL-stimulated EC-EVs) were significantly higher compared with those treated with HM-EVs that were isolated from unstimulated HCAECs ( Figure 5A -a-c, p < 0.01). Similar trends were observed in OROþ cells ( Figure 5B , p < 0.01). Moreover, we examined the effects of EC-EVs on lipid levels in HMDMs that were exposed to ox-LDL using highperformance liquid chromatography. We observed significantly higher FC, CE, and TC levels in HMDMs in the presence of ox-LDL-stimulated EC-EVs compared with those from unstimulated EC-EVs (Table 1 , all p < 0.05).
We also found that HMDMs exposed to EC-EVs promoted basal and ox-LDL-stimulated activity of the NF-kBdependent luciferase reporter ( Figure 3B , both p < 0.05). Lipid accumulation in HMDMs exposed to ox-LDL was inhibited by the IKK inhibitor TPCA-1 compared with those treated with ox-LDL alone (Supplementary Figure 2, Supplementary  Table 2 , p < 0.05).
HM-EVs/EC-EVs transfer miRNA-4306 to target HCAECs/HMDMs
Several independent approaches were used to confirm that miR-4306 could be transferred directly to HCAECs and HMDMs. First, we observed markedly higher miR-4306 levels in HCAECs and HMDMs after incubation with the HM-EVs or ECEVs for 12 hours compared with before incubation ( Figure 6A , B, p < 0.01). Additionally, with increasing EV concentrations, a dose-dependent increase in miR-4306 in HCAECs and HMDMs was observed ( Figure 6A , B, both p < 0.01).
We then knocked down miR-4306 expression in HCAECs and HMDMs, which resulted in significantly lower miR-4306 levels in HM-EVs and EC-EVs Additionally, pre-miR-4306 levels in recipient HCAECs and HMDMs were not altered by incubation with either HM-EVs or EC-EVs ( Figure 6A, B) . This finding indicated that the increase in miR-4306 level in cells was not due to de novo microRNA biosynthesis, but was directly derived from delivery by EVs. We also pretreated HCAECs and HMDMs with the miR-4306 derived from ox-LDLstimulated HM-EVs inhibits capillary tubule formation of HCAECs through the VEGFA/Akt/NF-jB signaling pathway
We found significantly higher HM-EVcontained miR-4306 levels after HMDM activation with ox-LDL compared with baseline (p < 0.01, Supplementary Figure  3b) . We then assessed whether miR-4306 can inhibit the proliferation, migration, and angiogenesis of HCAECs. HCAECs were transfected with miR-4306 mimics (Supplementary Figure 3C) . We found that overexpression of miR-4306 only slightly suppressed (non-significant) proliferation and migration of HCAECs (Supplementary Figure 5A-D) . However, capillary tubule formation of HCAECs was markedly inhibited by miR-4306 mimics (p < 0.01 versus miRNA control, Figure 7A , B). HM-EVs plus transfection with the miR-4306 inhibitor abolished the inhibitory effects of HM-EVs on capillary tubule formation of HCAECs ( Figure 2D , p < 0.05; Figure 2F -d, p < 0.01).
According to the miRBase Target database (http://www.mirbase.org), we speculated that VEGFA was a target gene of miR-4306. To identify direct repression of VEGFA by miR-4306, the VEGFA 3 0 UTR was cloned into a luciferase reporter plasmid and the resulting plasmid was transfected into 293T cells combined with or without treatment with miR-4306. Luciferase reporter activity was significantly lower following incubation with miR-4306 compared with miRNA control (p < 0.05, Figure 8A ). VEGFA protein expression in HCAECs transfected with the miR-4306 mimic or incubated with HM-EVs was significantly lower compared with that in controls ( Figure 8B , D, both p < 0.01). Moreover, we found that VEGFA protein levels in HCAECs treated with HM-EVs from patients with CAD were significantly lower than those in controls ( Figure 8C , p < 0.05).
VEGFA plays a role in promoting PI3K/ Akt-dependent EC angiogenesis. 8 We constructed a VEGFA lentiviral expression vector without 3 0 -UTR and infected HCAECs. VEGFA expression was restored after VEGFA lentiviral infection ( Figure 8D ). Akt signaling pathway activation was decreased after miR-4306 Table 2 ). Transfection with the miR-4306 inhibitor could partly abolish enhancement of lipid accumulation in HMDMs treated with EC-EVs ( Figure 5A, B) .
Overexpression of miR-4306 in HMDMs upregulated the Akt signaling pathway and NF-jB activity ( Figure 9C , p < 0.01 versus the lentivector group; Figure 3B , p < 0.05 versus the ox-LDL group). At the same time, transfection with the miR-4306 inhibitor abrogated the improvement in NF-kB signaling in cells treated with EC-EVs ( Figure 3B) .
Discussion
In the current study, we observed that HM-EV-derived miRNA-4306 expression was EVs are released in biological fluids under basal conditions and in pathological settings. Circulating levels of EVs of different cellular origins are increased in cardiovascular diseases and in various conditions associated with cardiovascular risk, 9 including smoking, 10 dyslipidemia, 11 diabetes mellitus, 12 and hypertension. 13 Consistent with these results, we found that HM-EV levels were significantly increased in CAD. We also found that EV levels in ox-LDLstimulated HMDMs and HCAECs were markedly higher compared with basal levels. Although miRNA profiles of EVs are significantly different from those of their maternal cells, 7 we observed that high expression of miR-4306 was decreased in HCAECs and HMDMs when exposed to ox-LDL. This finding suggests that the same miRNAs can be present in similar proinflammatory situations, regardless of the cells of origin.
Recent studies have indicated that EVs isolated from healthy individuals or EVs released under normal in vitro conditions have no effects on cellular function. 14, 15 Our results are in agreement with these previous reports. The angiogenesis abilities of HCAECs and lipid formation of HMDMs did not change when cells were cocultured with EVs from unstimulated cells or from control individuals. Our results indicated that EVs from ox-LDL-stimulated HMDMs dramatically inhibited proliferation, migration, and capillary tubule formation of HCAECs. However, HM-EV-contained miR-4306 suppressed the angiogenesis abilities of HCAECs. The effect of factors other than HM-EVderived miR-4306 on proliferation and migration of HCAECs cannot be excluded. Indeed, most vesicle isolation procedures 
